1/5/2024 0 Comments Outset medical ipo price![]() ![]() The Silk Road IPO garnered lots of attention from investors, with one IPO research firm giving the company its highest rating. Via: Investor's Business Daily Medical device company Silk Road Medical ( SILK) priced its initial public offering at 20 a share, at the high end of its recently raised expected range. The offering is expected to close on April 8, 2019, subject to the satisfaction of customary closing conditions. Silk Road Medical will not receive any proceeds from the sale of shares of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Silk Road Medical, are expected to be approximately $120 million. Silk Road Medical’s common stock is expected to begin trading on The Nasdaq Global Market on April 4, 2019, under the ticker symbol “SILK”. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. All of the shares of common stock are being offered by Silk Road Medical. ![]() Via: GlobeNewsWire SUNNYVALE, Calif., Ap(GLOBE NEWSWIRE) - Silk Road Medical, Inc. (Nasdaq: SILK) (“Silk Road Medical”) today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $20.00 per share. New Hanover Regional Medical Center is also considered a TCAR Center of Excellence, and there are four surgeons who can perform this procedure in Wilmington. It was performed at New Hanover Regional Medical Center for the first time in early 2018. Michael Patton and Thomas Eskew, vascular partners at Wilmington Surgical Associates, were the first surgeons in Eastern North Carolina to perform this procedure. TCAR is a very new surgical procedure for patients at high risk of stroke. Michael Patton of Wilmington Surgical Associates, located at 1414 Medical Center Drive, is one of the few in town who can perform TCAR, and has some information on this procedure. ![]() Transcarotid artery revascularization (TCAR) is one such procedure that can change the lives of patients at risk for stroke.ĭr. Thankfully, the medical field is rapidly advancing, and new techniques and procedures are created every year. Stroke Awareness Month, which occurs in May, is quickly approaching, which makes this a good time to discuss the medical advances in this area. Via: The Times-News The Centers for Disease Control and Prevention reports that nearly 800,000 people in the United States have suffered strokes. Tablo has a proprietary suite of sensors and data sets that can allow it to merge data from the machine and the patient in order to automatically adjust treatment parameters and customize therapy to an individual patient’s needs, all without interrupting clinic workflow. These sub-optimal outcomes are due in part to dialysis treatment decisions driven by incomplete, imprecise physiologic measurements and a one-size-fits-all approach to treatment planning. Department of Health and Human Services and the American Society of Nephrology to support innovative strategies for tackling kidney disease, a space that has been historically underfunded despite a growing patient population and poor patient outcomes, including high mortality and low quality of life. The KidneyX Redesign Dialysis Competition is a partnership between the U.S. Outset’s winning concept seeks to couple data from Tablo’s unique set of sensors and automation capabilities with physiologic data from the patient to deliver personalized dialysis treatments, ultimately improving outcomes for patients. SAN JOSE, Calif.-( BUSINESS WIRE)-Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that a project featuring the Tablo™ Hemodialysis System has been selected as a winner of the KidneyX Redesign Dialysis Competition. Via: BusinessWire Company’s Research Initiative Recognized as Novel, Innovative Approach to Deliver More Personalized Dialysis Treatment
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |